Glucocorticoid receptor signaling in bone cells

Trends in Molecular Medicine

Volumn 18, Issue 6, 2012, Pages 348-359

  Moutsatsou, Paraskevi ^a   Kassi, Eva ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Glucocorticoid receptor (GR); Glucocorticoids (GCs); GR dimerization; Osteoblast; Osteoclast; Osteocyte; Selective GR agonists (SEGRAs)

Indexed keywords

BIM PROTEIN; CASPASE 6; COLLAGENASE 3; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FAS LIGAND; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GRANZYME A; GROWTH HORMONE; HYDROCORTISONE; I KAPPA B; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LIPOCORTIN 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; OSTEOCALCIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P50; SOMATOMEDIN C; STAT5 PROTEIN; SURVIVIN; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BONE CELL; BONE DENSITY; BONE REMODELING; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING DISEASE; DEXAMETHASONE SUPPRESSION TEST; DNA POLYMORPHISM; DOWN REGULATION; GENE STRUCTURE; HUMAN; HYPERCORTISOLISM; JUVENILE RHEUMATOID ARTHRITIS; LIPID METABOLISM; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; PROTEIN STRUCTURE; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE DENSITY; CELL DIFFERENTIATION; CELL PROLIFERATION; GLUCOCORTICOIDS; HUMANS; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; RECEPTORS, GLUCOCORTICOID;

EID: 84861842592     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.04.005     Document Type: Review

References (85)

1. Mazziotti G., et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 2006, 17:144-149.
2. den Uyl D., et al. Advances in glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep. 2011, 13:233-240.
3. Weinstein R.S., et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010, 9:147-161.
4. Yang M., et al. Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation. Bone 2010, 47:573-582.
5. Manenschijn L., et al. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann. N.Y. Acad. Sci. 2009, 1179:179-198.
6. Canalis E., et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 2007, 18:1319-1328.
7. Smith E., et al. Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle. Dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes. J. Biol. Chem. 2000, 275:19992-20001.
8. McMaster A., Ray D.W. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects. Exp. Physiol. 2007, 92:299-309.
9. Kleiman A., Tuckermann J.P. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol. Cell Endocrinol. 2007, 275:98-108.
10. De Bosscher K. Selective glucocorticoid receptor modulators. J. Steroid Biochem. Mol. Biol. 2010, 120:96-104.
11. Gross K.L., Cidlowski J.A. Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol. Metab. 2008, 19:331-339.
12. Lu N.Z., Cidlowski J.A. Glucocorticoid receptor isoforms generate transcription specificity. Trends Cell Biol. 2006, 16:301-307.
13. Surjit M., et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011, 145:224-241.
14. Nicolaides N.C., et al. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010, 75:1-12.
15. Song I.H., Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol. Cell Endocrinol. 2006, 246:142-146.
16. Strehl C., et al. Origin and functional activity of the membrane-bound glucocorticoid receptor. Arthritis Rheum. 2011, 63:3779-3788.
17. Koufali M.M., et al. The dynamic localization of the glucocorticoid receptor in rat C6 glioma cell mitochondria. Mol. Cell Endocrinol. 2003, 209:51-60.
18. Frijters R., et al. Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC Genomics 2010, 11:359.
19. Bhattacharyya S., et al. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 2007, 109:4313-4319.
20. Unterberger C., et al. Role of STAT3 in glucocorticoid-induced expression of the human IL-10 gene. Mol. Immunol. 2008, 45:3230-3237.
21. Chen T.L. Inhibition of growth and differentiation of osteoprogenitors in mouse bone marrow stromal cell cultures by increased donor age and glucocorticoid treatment. Bone 2004, 35:83-95.
22. Masuyama A., et al. Characteristics of steroid hormone receptors in cultured MC3T3-E1 osteoblastic cells and effect of steroid hormones on cell proliferation. Calcif. Tissue Int. 1992, 51:376-381.
23. Liesegang P., et al. Human osteoblast-like cells contain specific, saturable, high-affinity glucocorticoid, androgen, estrogen, and 1 alpha, 25-dihydroxycholecalciferol receptors. J. Androl. 1994, 15:194-199.
24. Silvestrini G., et al. Cytochemical demonstration of the glucocorticoid receptor in skeletal cells of the rat. Endocr. Res. 1999, 25:117-128.
25. Silvestrini G., et al. Localization of the glucocorticoid receptor mRNA in cartilage and bone cells of the rat. An in situ hybridization study. Eur. J. Histochem. 2003, 47:245-252.
26. Abu E.O., et al. The localization of the functional glucocorticoid receptor alpha in human bone. J. Clin. Endocrinol. Metab. 2000, 85:883-889.
27. Beavan S., et al. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J. Bone Miner. Res. 2001, 16:1496-1504.
28. Solakidi S., et al. Differential distribution of glucocorticoid and estrogen receptor isoforms: localization of GRbeta and ERalpha in nucleoli and GRalpha and ERbeta in the mitochondria of human osteosarcoma SaOS-2 and hepatocarcinoma HepG2 cell lines. J. Musculoskelet. Neuronal. Interact. 2007, 7:240-245.
29. Haussler M.R., et al. Glucocorticoid receptor in clonal osteosarcoma cell lines: a novel system for investigating bone active hormones. Biochem. Biophys. Res. Commun. 1980, 94:373-380.
30. Rogatsky I., et al. Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids. Mol. Cell Biol. 1999, 19:5036-5049.
31. Takayama S., et al. The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-beta-catenin complex. J. Biol. Chem. 2006, 281:17856-17863.
32. Horsch K., et al. Mitogen-activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol. Endocrinol. 2007, 21:2929-2940.
33. Shipp L.E., et al. Transcriptional regulation of human dual specificity protein phosphatase 1 (DUSP1) gene by glucocorticoids. PLoS ONE 2010, 5:e13754.
34. Ito S., et al. Glucocorticoids induce the differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal osteoblast differentiation. Bone 2007, 40:84-92.
35. Hofbauer L.C., Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol. Endocrinol. 2009, 23:1525-1531.
36. van der Laan S., et al. Chromatin immunoprecipitation scanning identifies glucocorticoid receptor binding regions in the proximal promoter of a ubiquitously expressed glucocorticoid target gene in brain. J. Neurochem. 2008, 106:2515-2523.
37. Zhang W., et al. Regulation of mesenchymal stem cell osteogenic differentiation by glucocorticoid-induced leucine zipper (GILZ). J. Biol. Chem. 2008, 283:4723-4729.
38. Lekva T., et al. The glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous Cushing's syndrome and may play a role in glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 2010, 95:246-255.
39. Tornvig L., et al. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif. Tissue Int. 2001, 69:46-50.
40. Wu R.W., et al. Cannabinoid receptor 1 regulates ERK and GSK-3beta-dependent glucocorticoid inhibition of osteoblast differentiation in murine MC3T3-E1 cells. Bone 2011, 49:1255-1263.
41. Meisler N., et al. Glucocorticoids coordinately regulate type I collagen pro alpha 1 promoter activity through both the glucocorticoid and transforming growth factor beta response elements: a novel mechanism of glucocorticoid regulation of eukaryotic genes. J. Cell Biochem. 1995, 59:376-388.
42. Pierotti S., et al. Pre-receptorial regulation of steroid hormones in bone cells: insights on glucocorticoid-induced osteoporosis. J. Steroid Biochem. Mol. Biol. 2008, 108:292-299.
43. Hayami T., et al. Dexamethasone's enhancement of osteoblastic markers in human periodontal ligament cells is associated with inhibition of collagenase expression. Bone 2007, 40:93-104.
44. Ogata Y., et al. Glucocorticoid regulation of bone sialoprotein (BSP) gene expression. Identification of a glucocorticoid response element in the bone sialoprotein gene promoter. Eur. J. Biochem. 1995, 230:183-192.
45. Yamauchi M., et al. AP-1 regulation of the rat bone sialoprotein gene transcription is mediated through a TPA response element within a glucocorticoid response unit in the gene promoter. Matrix Biol. 1996, 15:119-130.
46. Fatherazi S., et al. Phosphate regulates osteopontin gene transcription. J. Dent. Res. 2009, 88:39-44.
47. Hu F., et al. deltaEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Biochim. Biophys. Acta. 2011, 1809:200-210.
48. Delany A.M., et al. Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms. J. Biol. Chem. 1995, 270:26607-26612.
49. Mikami Y., et al. Bone morphogenetic protein 2 and dexamethasone synergistically increase alkaline phosphatase levels through JAK/STAT signaling in C3H10T1/2 cells. J. Cell Physiol. 2010, 223:123-133.
50. Jager M., et al. Dexamethasone modulates BMP-2 effects on mesenchymal stem cells in vitro. J. Orthop. Res. 2008, 26:1440-1448.
51. Matsumoto Y., et al. Estrogen and glucocorticoid regulate osteoblast differentiation through the interaction of bone morphogenetic protein-2 and tumor necrosis factor-alpha in C2C12 cells. Mol. Cell Endocrinol. 2010, 325:118-127.
52. Liu Y., et al. Glucocorticoid regulation of human BMP-6 transcription. Bone 2004, 35:673-681.
53. Olkku A., Mahonen A. Calreticulin mediated glucocorticoid receptor export is involved in beta-catenin translocation and Wnt signalling inhibition in human osteoblastic cells. Bone 2009, 44:555-565.
54. Kim H.J., et al. Glucocorticoids and the osteoclast. Ann. N.Y. Acad. Sci. 2007, 1116:335-339.
55. Pantschenko A.G., et al. Effect of osteoblast-targeted expression of bcl-2 in bone: differential response in male and female mice. J. Bone Miner. Res. 2005, 20:1414-1429.
56. O'Brien C.A., et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004, 145:1835-1841.
57. Espina B., et al. Regulation of bim in glucocorticoid-mediated osteoblast apoptosis. J. Cell Physiol. 2008, 215:488-496.
58. Lu N.Z., et al. Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. Mol. Cell Biol. 2007, 27:7143-7160.
59. Lynch J.T., et al. The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression. Mol. Cancer 2010, 9:38.
60. Gross K.L., et al. Glucocorticoid receptor alpha isoform-selective regulation of antiapoptotic genes in osteosarcoma cells: a new mechanism for glucocorticoid resistance. Mol. Endocrinol. 2011, 25:1087-1099.
61. Rippo M.R., et al. Dexamethasone affects Fas- and serum deprivation-induced cell death of human osteoblastic cells through survivin regulation. Int. J. Immunopathol. Pharmacol. 2010, 23:1153-1165.
62. Kosa J.P., et al. The protective role of bone morphogenetic protein-8 in the glucocorticoid-induced apoptosis on bone cells. Bone 2011, 48:1052-1057.
63. Wintermantel T.M., et al. Genetic dissection of corticosteroid receptor function in mice. Horm. Metab. Res. 2004, 36:387-391.
64. Rauch A., et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010, 11:517-531.
65. Rauch A., et al. An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J. 2011, 25:1323-1332.
66. Jewell C.M., et al. Complex human glucocorticoid receptor dim mutations define glucocorticoid induced apoptotic resistance in bone cells. Mol. Endocrinol. 2012, 26:244-256.
67. Weinstein R.S. Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone 2010, 46:564-570.
68. Plotkin L.I., et al. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J. Biol. Chem. 2007, 282:24120-24130.
69. Xiong J., et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 2011, 17:1235-1241.
70. Kondo T., et al. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J. Cell Biochem. 2008, 103:335-345.
71. Jia D., et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006, 147:5592-5599.
72. Rauner M., et al. Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. Endocrinology 2011, 152:103-112.
73. Reyes-Moreno C., Koutsilieris M. Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton. Clin. Exp. Metastasis 1997, 15:205-217.
74. Claudino M., et al. Down-regulation of expression of osteoblast and osteocyte markers in periodontal tissues associated with the spontaneous alveolar bone loss of interleukin-10 knockout mice. Eur. J. Oral Sci. 2010, 118:19-28.
75. Kim H.J. New understanding of glucocorticoid action in bone cells. BMB Rep. 2010, 43:524-529.
76. Kim H.J., et al. Glucocorticoids suppress bone formation via the osteoclast. J. Clin. Invest. 2006, 116:2152-2160.
77. Weinstein R.S., et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J. Clin. Invest. 2002, 109:1041-1048.
78. Szappanos A., et al. BclI polymorphism of the glucocorticoid receptor gene is associated with decreased bone mineral density in patients with endogenous hypercortisolism. Clin. Endocrinol. (Oxf.) 2009, 71:636-643.
79. van Schoor N.M., et al. Serum fasting cortisol in relation to bone, and the role of genetic variations in the glucocorticoid receptor. Clin. Endocrinol. (Oxf.) 2007, 67:871-878.
80. Kostik M.M., et al. Glucocorticoid receptor gene polymorphism and juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 2011, 9:2.
81. te Winkel M.L., et al. Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia. Haematologica 2010, 95:752-759.
82. Tzanela, M. et al. Clinical and biochemical impact of BCL1 polymorphic genotype of the glucocorticoid receptor gene in patients with adrenal incidentalomas. J. Endocrinol. Invest. (in press).
83. Huizenga N.A., et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab. 1998, 83:144-151.
84. Majnik J., et al. A rapid and simple method for detection of Asn363Ser polymorphism of the human glucocorticoid receptor gene. J. Steroid Biochem. Mol. Biol. 2004, 92:465-468.
85. Peng Y.M., et al. Sex-specific association of the glucocorticoid receptor gene with extreme BMD. J. Bone Miner. Res. 2008, 23:247-252.